Literature DB >> 9231883

Multistep carcinogenesis of breast cancer and tumour heterogeneity.

M W Beckmann1, D Niederacher, H G Schnürch, B A Gusterson, H G Bender.   

Abstract

Breast cancer emerges by a multistep process which can be broadly equated to transformation of normal cells via the steps of hyperplasia, premalignant change and in situ carcinoma. The elucidation of molecular interdependencies, which lead to development of primary breast cancer, its progression, and its formation of metastases is the main focus for new strategies targetted at prevention and treatment. Cytogenetic and molecular genetic analysis of breast cancer samples demonstrates that tumour development involves the accumulation of various genetic alterations including amplification of oncogenes and mutation or loss of tumour suppressor genes. Amplification of certain oncogenes with concomitant overexpression of the oncoprotein seems to be specific for certain histological types. Loss of normal tumour suppressor protein function can occur through sequential gene mutation events (somatic alteration) or through a single mutational event of a remaining normal copy, when a germline mutation is present. The second event is usually chromosome loss, mitotic recombination, or partial chromosome deletion. Chromosome loci 16q and 17p harbour tumour suppressor genes, which seem to be pathognomonic for the development or progression of a specific histological subtype. There are an overwhelming number of abnormalities that have been identified at the molecular level which fit the model of multistep carcinogenesis of breast cancer. When the functions of all of these genes are known and how they participate in malignant progression, we will have the tools for a more rational approach to diagnosis, prevention and treatment. This review deals only with the factors that are involved in the conversion of a normal breast cell into a malignant cell rather than those required for invasion and metastases. A key critical long-term step in the molecular analysis of breast cancer will be to link the specific molecular damage with the effects of environmental carcinogens.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231883     DOI: 10.1007/s001090050128

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  61 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  CD95 ligand expression as a mechanism of immune escape in breast cancer.

Authors:  M Müschen; C Moers; U Warskulat; J Even; D Niederacher; M W Beckmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

3.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

4.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

5.  The long and short of chromosome 11 in breast cancer.

Authors:  I F Newsham
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

6.  Invasive Breast Cancer Preferably and Predominantly Occurs at the Interface Between Fibroglandular and Adipose Tissue.

Authors:  Wenlian Zhu; Susan Harvey; Katarzyna J Macura; David M Euhus; Dmitri Artemov
Journal:  Clin Breast Cancer       Date:  2016-07-28       Impact factor: 3.225

7.  Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification.

Authors:  A Gama; A Alves; F Schmitt
Journal:  Virchows Arch       Date:  2008-08-02       Impact factor: 4.064

8.  Aberrant leukocyte infiltration: a direct trigger for breast tumor invasion and metastasis.

Authors:  Yan-Gao Man
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

9.  Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.

Authors:  Mansoor Ahmed; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-05-07       Impact factor: 27.401

10.  Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.

Authors:  Mercedes Zurita; Pedro C Lara; Rosario del Moral; Blanca Torres; José Luis Linares-Fernández; Sandra Ríos Arrabal; Joaquina Martínez-Galán; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.